Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 4/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420038 | 0.79 | PGR (0.41) | MAPTPTGS2 | |
| SCHEMBL7005795 | 0.77 | PTGS2 (0.39) | MAPTPTGS2PDE3BPDE3ARAB9A | |
| SCHEMBL3333548 | 0.76 | ALDH1A1 (0.36) | KMT2ALMNAMAPTPDE3APARP10 | |
| SCHEMBL15000221 | 0.76 | RAB9A (0.40) | KMT2ALMNAPTGS2PDE3BPDE3A | |
| SCHEMBL16972712 | 0.74 | CA2 (0.46) | KMT2APTGS2MEN1PKM | |
| SCHEMBL27465488 | 0.73 | — | — | |
| SCHEMBL27484474 | 0.73 | — | — | |
| SCHEMBL286665 | 0.73 | SENP1 (0.36) | KMT2ALMNAMAPTPTGS2NPC1 | |
| SCHEMBL17239814 | 0.73 | SENP1 (0.36) | KMT2ALMNAMAPTPTGS2NPC1 | |
| SCHEMBL1420042 | 0.72 | TGFBR1 (0.37) | MAPTPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-11-12 | — | — | US | claimed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | claimed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-3020716-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | Forum Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-3020716-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | Forum Pharmaceuticals Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| CN-105125547-A | FORUM PHARMACEUTICALS INC | FORUM PHARMACEUTICALS INC | 2015-12-09 | — | — | CN | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | FMR LLC | 2010-11-18 | — | — | US | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128995-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | KMT2A 2279/4885LMNA 3565/4885MAPT 476/4885 |
| US-20150322069-A1 | PHENOXYMETHYL HETEROCYCLIC COMPOUNDS | PDE3A, PDE2A, PDE5A | KMT2A 1618/4885LMNA 1667/4885MAPT 1299/4885 |
| US-20100292238-A1 | Phenoxymethyl Heterocyclic Compounds | PDE3A, PDE2A, PDE5A | KMT2A 1618/4885LMNA 1667/4885MAPT 1299/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | KMT2A 2279/4885LMNA 3565/4885MAPT 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.